<div id="readability-page-1"><p>4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the business's stock in a transaction on Monday, November 17th. The stock was sold at an average price of $10.59, for a total value of $17,314.65. Following the transaction, the insider directly owned 3,594 shares of the company's stock, valued at $38,060.46. The trade was a 31.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website.</p><p>Scott Bizily also recently made the following trade(s): </p><ul><li>On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $32,136.00. </li><li>On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.17, for a total value of $16,627.95. </li><li>On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $24,080.00. </li><li>On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total transaction of $19,256.00. </li></ul><h2>4D Molecular Therapeutics Trading Up 7.0%</h2><p>NASDAQ:FDMT traded up $0.71 during mid-day trading on Wednesday, hitting $10.80. The stock had a trading volume of 904,864 shares, compared to its average volume of 1,057,282. 4D Molecular Therapeutics, Inc. has a twelve month low of $2.23 and a twelve month high of $12.34. The stock has a 50-day simple moving average of $9.54 and a two-hundred day simple moving average of $6.43. The company has a market capitalization of $617.00 million, a PE ratio of -2.88 and a beta of 2.96. </p><p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million.  Sell-side analysts predict that  4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities analysts recently commented on FDMT shares. Barclays dropped their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, November 11th. Leerink Partners  reaffirmed an &#34;outperform&#34; rating and set a $17.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Morgan Stanley raised 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a research report on Friday, November 7th. Royal Bank Of Canada boosted their target price on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $28.70.</p><p><b>Read Our Latest Report on FDMT</b></p><h2>Institutional Trading of 4D Molecular Therapeutics</h2><p>A number of large investors have recently made changes to their positions in FDMT. Armistice Capital LLC grew its stake in  4D Molecular Therapeutics by 265.3% during the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company's stock worth $9,524,000 after buying an additional 796,000 shares during the last quarter.  Wexford Capital LP acquired a new stake in shares of  4D Molecular Therapeutics in the third quarter valued at approximately $41,000.  Prelude Capital Management LLC boosted its holdings in shares of  4D Molecular Therapeutics by 11.1% in the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company's stock valued at $200,000 after acquiring an additional 2,300 shares during the period.  Parkman Healthcare Partners LLC purchased a new position in shares of  4D Molecular Therapeutics during the third quarter worth approximately $1,738,000.  Finally, Brevan Howard Capital Management LP acquired a new position in shares of  4D Molecular Therapeutics in the 3rd quarter valued at $143,000. 99.27% of the stock is owned by institutional investors and hedge funds. </p><h2>About 4D Molecular Therapeutics</h2> (Get Free Report)<p>4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than 4D Molecular Therapeutics</li><li>Using the MarketBeat Dividend Yield Calculator</li><li>onsemi Places a $6 Billion Bet on Its Own Stock</li><li>How to Profit From Value Investing </li><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li><li>How to Use Stock Screeners to Find Stocks</li><li>End the Year Strong With These 3 Comeback Champions</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

FDMT

<p>Scott Bizily, an insider at 4D Molecular Therapeutics, sold 1,635 shares for $17,314.65, reducing his ownership by 31.27%. The sale was disclosed in an SEC filing. The company recently reported quarterly earnings, beating estimates slightly, and analysts have mixed ratings on the stock. Institutional investors have adjusted their positions in the company, with Armistice Capital significantly increasing its stake.</p>

Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock